Overview
OLYS Pharma targets treatments for painful chronic inflammatory conditions through topical/transdermal modulation of pain, neurotransmission, and innate immune response to break the pro-inflammatory cycle of neurogenic inflammation. The research includes modulation of dorsal root ganglion (DRG) activity to treat pain and low-grade inflammation in organs while preventing brain remodeling.
Key people
Something wrong or missing? Send an update. Fixed within 24 hours.